Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nathalie Giuly"'
Autor:
Dimitri Loureiro, Issam Tout, Stéphanie Narguet, Cheikh Mohamed Bed, Morgane Roinard, Ahmad Sleiman, Nathalie Boyer, Nathalie Pons‐Kerjean, Corinne Castelnau, Nathalie Giuly, Dorothy Tonui, Vassili Soumelis, Jamel El Benna, Patrick Soussan, Richard Moreau, Valérie Paradis, Abdellah Mansouri, Tarik Asselah
Publikováno v:
Hepatology. 77:1348-1365
Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters mitochondria in experimental models. Our goal was to investigate whether HBV might alter liver mitochondria also in humans, and the resulting mitochondrial stress might account
Autor:
Stéphanie Narguet, Abdellah Mansouri, Nathalie Giuly, Zeina Louis, Nathalie Boyer, Patrick Marcellin, Sabrina Menasria Benazzouz, Corinne Castelnau, Issam Tout, Dimitri Loureiro, Nathalie Pons-Kerjean, Tarik Asselah
Publikováno v:
Liver International. 41:30-37
Hepatitis delta virus (HDV) infection is a defective virus requiring hepatitis B virus (HBV) for its complete replication cycle. HDV is a small hepatotropic RNA virus and around 15 to 25 million people worldwide are living with chronic hepatitis delt
Autor:
Dimitri Loureiro, Issam Tout, Cheikh Mohemed Bed, Morganer Roinard, Ahmad Sleiman, Boyer Nathalie, Stephanie Narguet, Nathalie Pons-Kerjean, Corinne Castelnau, Nathalie Giuly, Vassili Soumelis, Jamel El Benna, Patrick Soussan, Richard Moreau, Valérie Paradis, Abdel Mansouri, Tarik Asselah
Publikováno v:
Journal of Hepatology. 77:S245-S246
Autor:
Nathalie Giuly, Stéphanie Narguet, Frédéric Le Gal, Patrick Marcellin, Ségolène Brichler, Sarah Maylin, Cheikh Mohamed Bed, Malek Abazid, Abdellah Mansouri, Valérie Bouton, Dimitri Loureiro, Athenaïs Gerber, Tarik Asselah, Emmanuel Gordien, Issam Tout, Nathalie Boyer, Corinne Castelnau
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 41(7)
Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Bulevirtide (BLV, Hepcludex® ) is an HDV/HBV entry inhibitor approved in June 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and comp